文献速递乳腺乳腺X线

数字乳腺断层合成与数字乳腺X线摄影检出乳腺癌的病理特征比较:一项汇总比较分析

Pathologic Characteristics of Breast Cancers Detected With Digital Mammography Versus Digital Breast Tomosynthesis: A Pooled Comparative Analysis.
PubMed 文献 · Acad Radiol · 2026-08-13

该汇总比较分析纳入6项提供可提取病理终点数据的比较性筛查研究,比较数字乳腺断层合成(DBT)与数字乳腺X线摄影(DM)检出乳腺癌的病理特征。混合效应模型显示,DBT与DM在肿瘤分级、淋巴结状态、肿瘤大小、受体标志物及Ki67阳性率方面均无足够证据表明存在显著差异。结论认为,当前比较证据提示DBT可提高乳腺癌检出率,但未显示相对于DM一致的病理特征偏移。

要点

  • DBT与DM检出乳腺癌在组织学分级、淋巴结状态及肿瘤大小上无显著差异。
  • 受体标志物及Ki67分析因报告稀疏和来源定义异质而受限。
  • DBT提高检出率但未改变检出癌的病理特征谱。

核心结论

  • 当前比较证据表明DBT较DM增加乳腺癌检出,但未显示检出癌的病理特征存在一致偏移。
  • 因研究方案、病理报告及终点可获得性各异,结论需谨慎解读。

研究设计与样本

  • 研究为汇总比较分析,检索PubMed、Embase和Cochrane Library至2026年2月。
  • 主要分级分析纳入809例浸润性癌(DBT检出261例,DM检出548例)。
  • 淋巴结状态分析纳入818例浸润性癌(DBT检出263例,DM检出555例)。
  • 采用混合效应逻辑回归(研究水平随机截距)及随机效应风险差荟萃分析作为敏感性分析。

诊断标准与关键数值

  • 3级肿瘤比例:DM 35.7%(95%CI 23.8%-49.7%) vs DBT 29.7%(95%CI 18.8%-43.5%),P=.15。
  • 淋巴结阳性比例:DM 36.8%(95%CI 31.6%-42.4%) vs DBT 32.8%(95%CI 27.2%-39.0%),P=.16。
  • 肿瘤大小>10 mm比例:DM 78.0%(95%CI 63.7%-87.7%) vs DBT 75.0%(95%CI 59.4%-86.0%),P=.44。
  • 三阴性表型、HER2阳性、ER/PR阳性及Ki67阳性均无足够证据表明存在显著差异。

临床应用与阅片要点

  • 阅片报告时不必因DBT检出而预期肿瘤分级或淋巴结状态更有利。
  • DBT检出的乳腺癌病理特征可与DM检出者相似,报告应基于实际影像与病理所见。
  • 受体及Ki67状态需依据病理报告,影像不能替代。

局限性

  • 研究方案、病理报告及终点可获得性在各研究间存在差异。
  • 受体及Ki67分析因报告稀疏和来源定义异质而受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Although digital breast tomosynthesis (DBT) improves screening performance relative to digital mammography (DM), it remains uncertain whether DBT changes the pathologic profile of detected cancers. We compared tumor grade, nodal status, tumor size, receptor markers, and related pathology features across comparative screening studies.

METHODS: We searched PubMed, Embase, and the Cochrane Library through February 2026. Thirteen comparative screening studies were summarized in the protocol/context table, and six comparative screening studies contributed extractable data to at least one quantitative pathology endpoint. The primary grade analysis included 809 invasive cancers (261 DBT-detected and 548 DM-detected), and the nodal-status analysis included 818 invasive cancers (263 DBT-detected and 555 DM-detected). We used mixed-effects logistic regression with a study-level random intercept and random-effects risk-difference meta-analysis as a sensitivity analysis.

RESULTS: Mixed-effects models showed insufficient evidence of major between-modality differences for grade 3 tumors (DM 35.7% [95% CI, 23.8%-49.7%] vs DBT 29.7% [18.8%-43.5%]; P=.15), node-positive disease (36.8% [31.6%-42.4%] vs 32.8% [27.2%-39.0%]; P=.16), tumor size >10 mm (78.0% [63.7%-87.7%] vs 75.0% [59.4%-86.0%]; P=.44), triple-negative phenotype, HER2 positivity, ER/PR positivity, or Ki67 positivity. Receptor and Ki67 analyses were limited by sparse reporting and heterogeneous source definitions.

CONCLUSION: Current comparative evidence suggests that DBT increases detection of breast cancers without demonstrating a consistent shift in pathologic profile relative to DM. These findings should be interpreted cautiously because study protocols, pathology reporting, and endpoint availability varied across studies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Ferre R, Benefield T, Kuzmiak CM, et al. Pathologic Characteristics of Breast Cancers Detected With Digital Mammography Versus Digital Breast Tomosynthesis: A Pooled Comparative Analysis. Acad Radiol. 2026. PMID: 42595635. doi:10.1016/j.acra.2026.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。